Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers

被引:16
|
作者
Kim, H [1 ]
Yun, M [1 ]
Kwon, KI [1 ]
机构
[1] Chungnam Natl Univ, Coll Pharm, Taejon 305764, South Korea
关键词
gliclazide; pharmacokinetics; pharmacodynamics; human;
D O I
10.1007/BF02976882
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Pharmacokinetic and pharmacodynamic properties of gliclazide were studied after an oral administration of gliclazide tablets in healthy volunteers. After an overnight fasting, gliclazide tablet was orally administered to 11 volunteers; Additional 10 volunteers were used as a control group (i.e., no gliclazide administration). Blood samples were collected, and the concentration determined for gliclazide and glucose up to 24 after the administration. Standard pharmacokinetic analysis was carried out for gliclazide. Pharmacodynamic activity of the drug was expressed by increase of glucose concentration (APG), by area under the increase of glucose concentration-time curve (AUC(DeltaPG)) or by the difference in increase of glucose concentration (DAPG) at each time between groups with and without gliclazide administration. Pharmacokinetic analysis revealed that C-max, T-max, CL/F (apparent clearance), V/F (apparent volume of distribution) and half-life of gliclazide were 4.69+/-1.38 mg/L, 3.45+/-1.11 h, 1.26+/-0.35 L/h, 17.78+/-5.27 L, and 9.99+/-2.15 h, respectively. When compared with the no drug administration group, gliclazide decreased significantly the AUC(DeltaPG) s at 1, 1.5, 2, 2.5, 3 and 4 h (p<0.05). The DeltaPGs were positively correlated with AUC(glidazide) at 1 and 1.5 h (p<0.05), and the correlation coefficient was maximum at 1 h (r = 0.642) and gradually decreased at 4 h after the administration. The AUC(DeltaPG)S were positively correlated with AUC(gliclazide) at 1, 2, 3 and 4 h (p<0.05), and the maximum correlation coefficient was obtained at 2 h (r=0.642) after the administration. The D-DeltaPG reached the maximum at 1 h, remained constant from 1 h to 3 h, and decreased afterwards. Therefore, these observations indicated that maximum hypoglycemic effect of gliclazide was reached at approximately at 1.5 h after the administration and the effect decreased, probably because of the homeostasis mechanism, in health volunteers.
引用
收藏
页码:564 / 568
页数:5
相关论文
共 50 条
  • [21] Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers
    Hamitouche, Noureddine
    Comets, Emmanuelle
    Ribot, Megane
    Alvarez, Jean-Claude
    Bellissant, Eric
    Laviolle, Bruno
    AAPS JOURNAL, 2017, 19 (03): : 727 - 735
  • [22] Evaluation of pharmacokinetic and pharmacodynamic similarity of an IDegAsp biosimilar versus the originator in healthy Chinese volunteers
    Liu, Hui
    Xiong, Yang
    Chen, Xinlei
    Yu, Hongling
    Lan, Li
    He, Wengang
    Wang, Wenjia
    Zhuang, Yulei
    Deng, Li
    Huang, Kanghua
    Guo, Linfeng
    Yu, Yerong
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2025, 34 (1-2) : 97 - 104
  • [23] Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers
    Noureddine Hamitouche
    Emmanuelle Comets
    Mégane Ribot
    Jean-Claude Alvarez
    Eric Bellissant
    Bruno Laviolle
    The AAPS Journal, 2017, 19 : 727 - 735
  • [24] Evaluation of the Bioequivalence and Pharmacokinetics of Two Formulations of Gliclazide in Healthy Chinese Volunteers Using Population Pharmacokinetic Approach
    Huang, Ji-han
    Huang, Xiao-hui
    Li, Lu-jin
    Li, Yun-fei
    Wang, Kun
    Zheng, Qing-shan
    LATIN AMERICAN JOURNAL OF PHARMACY, 2013, 32 (04): : 490 - 497
  • [25] Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers
    Zuurman, Lineke
    Passier, Paul C. C. M.
    de Kam, Marieke L.
    Kleijn, Huub J.
    Cohen, Adam F.
    van Gerven, Joop M. A.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (11) : 1689 - 1696
  • [26] Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers
    Ragueneau, I
    Poirier, JM
    Radembino, N
    Sao, AB
    Funck-Brentano, C
    Jaillon, P
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) : 453 - 456
  • [27] Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers
    Ramakrishnan, R
    Cheung, WK
    Wacholtz, MC
    Minton, N
    Jusko, WJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) : 991 - 1002
  • [28] Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers
    Zuurman, L.
    Passier, P. C. C. M.
    de Kam, M. L.
    Kleijn, H. J.
    Cohen, A. F.
    van Gerven, J. M. A.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (06) : 633 - 644
  • [29] Pharmacokinetic/pharmacodynamic research on three different infusion time regimens of linezolid in healthy Chinese volunteers
    Cai, Yun
    Bai, Nan
    Liu, Xu
    Liang, Beibei
    Wang, Jin
    Wang, Rui
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (09) : 765 - 771
  • [30] Pharmacokinetic/Pharmacodynamic Modeling of Psychomotor Impairment Induced by Oral Clonazepam in Healthy Volunteers
    dos Santos, Fabio Monteiro
    Saraiva Goncalves, Jose Carlos
    Caminha, Ricardo
    da Silveira, Gabriel Estolano
    de Miranda Neves, Claudia Silvana
    da Silva Gram, Karla Regina
    Ferreira, Carla Teixeira
    Jacqmin, Philippe
    Noel, Francis
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 566 - 574